Navigation Links
Convoy Therapeutics Granted Patent for Proprietary SPACE Technology
Date:9/25/2013

Oro Valley, AZ (PRWEB) September 25, 2013

Convoy Therapeutics, Inc. is proud to announce that the United States Patent and Trademark Office has granted a patent for the proprietary Skin Permeating And Cell Entering (SPACE) Peptide technology. The company obtained a worldwide exclusive license to in 2011 from University of California at Santa Barbara.

“The granting of this patent furthers the advancement of our technology and its many uses in the field,” states Dr. John Muraski, President and CEO of Convoy Therapeutics and its parent company ACTUS Biotechnologies, Inc. The company is currently working with a number of cosmetic and pharmaceutical partners to take advantage of its platform technology with a variety of molecules. Furthermore, Dr. Muraski states, “Our platform can be adapted to various active ingredients to enable penetration of large molecules past the outer layer of the skin and into the epidermis and dermis, and there is evidence that it can also enhance retention of some small molecules.” The recent addition of a team of professionals with substantial experience in the dermatology industry has expanded the capabilities of the company as they seek to market two reformulations in the coming 12-36 months: a high molecular weight topical Hyaluronic Acid cosmetic for the reduction of fine lines and wrinkles and Cyclopsorb™, a topical cyclosporine for the treatment of moderate to severe psoriasis.

The company’s Topical Hyaluronic Acid is a cosmetic application intended to maintain a smooth complexion between filler or toxin injections while being passively absorbed into the skin, reaching the epidermal and dermal layers. Convoy is currently completing safety studies and scale up. The company has an expected launch date for their Topical Hyaluronic Acid product in Q3, 2014.

Convoy’s second product, Cyclopsorb™, for the topical treatment of moderate to severe psoriasis, is currently in the fina
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
2. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
3. Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
4. Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
5. Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
6. PTC Therapeutics to Present at European Pediatric Neurology Society Congress
7. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
8. Adheron Therapeutics Names New Senior Leadership
9. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
10. Echo Therapeutics Sends Response to Shareholder Letter
11. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) ... (eslicarbazepine acetate) for use as a once-daily adjunctive therapy ... epilepsy who are not satisfactorily controlled with conventional therapy. ... patients under 18 years of age. ... and according to Epilepsy Canada, it affects 0.6% of ...
(Date:7/10/2014)... Deep Knowledge Ventures last week sponsored ... Longevity Research’ and welcomed a host of London-based ... Innovation Center for the event, organised by the ... The meeting highlighted the need for both philanthropic ... disease, as well as the crucial role of ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... , , BOTHELL, ... BLFS), a leading manufacturer and marketer of biopreservation tools for ... into a non-exclusive distribution agreement with STEMCELL Technologies, Inc., based ... StemCell Group of companies, is a leading provider of products ...
... international ports could be the most affordable approach to ... not carrying nuclear bombs, according to a paper being ... the Institute for Operations Research and the Management Sciences ... in place that relies on targeting only a small ...
... and Washington DC (July 27, 2009) According to a ... Making , a large-scale, covert anthrax attack on a ... extremely effective public health response, primarily because of expected ... to it. The article "Predicting Hospital Surge after ...
Cached Biology Technology:BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 4Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 2
(Date:7/10/2014)... July 7, 2014 According to ... "Electronic Access Control Systems Market Global Forecast, Market Share, ... global Electronic Access Control systems market was valued at ... grow at a CAGR of 12.6% from 2014 to ... million in 2019. Browse the full Electronic ...
(Date:7/10/2014)... NORTHFIELD, Ill. , July 9, 2014 /PRNewswire-USNewswire/ ... record (EHR), spurred in large part by meaningful ... way health care providers interact with laboratory information. ... well-versed in the field of clinical informatics in ... care. To address the educational needs ...
(Date:7/10/2014)... German . An ... a central step of photosynthesis in action for the first ... State University used the world,s most powerful X-ray flashlight at ... of a molecular complex called photosystem II as it splits ... oxygen in earth,s atmosphere. The researchers report their results in ...
Breaking Biology News(10 mins):Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4Scientists watch photosynthesis in action 2Scientists watch photosynthesis in action 3
... a common feature in IBS and in fact may be ... on a lactulose breath test may indicate SIBO. Antibiotics and ... SIBO, but the efficacy of probiotics is untested. A pilot ... Shirota (Yakult(R)) on intestinal fermentation patterns of IBS patients. After ...
... interoperability during ePassports EAC ... Interoperability Tests in Prague, DALLAS, Sept. 9 ... Slovenia again has,selected Entrust, Inc. (Nasdaq: ENTU ) ... based on the Extended,Access Control (EAC) standard. With this, ...
... its intellectual and innovative strengths the betterment of the ... the betterment of us all. According to its ... Property and Commercialization shows that the institution continues to ... productivity and delivering new ideas to the marketplace. ...
Cached Biology News:Is yakult helpful in the treatment of irritable bowel syndrome? 2Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 2Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 3Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 4Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 5A reputation for innovation 2
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Cyno macaque plasma and serum - various quantities available...
Biology Products: